Low-Risk Genomics--Maybe
Executive Summary
In biotech's early days, companies thought they could hedge their long-term bets by relatively inexpensive and much shorter-term plays in diagnostics. But finding diagnostics with enough value proved difficult. Now biotechs are at it again, focusing on the diagnostic implications of pharmacogenomics, the science of linking drug efficacy to genes, which can be used to sort out which patients will benefit from particular drugs.